| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
CYP3A4 (IC50 = 36.63 μM); CYP2C9 (IC50 = 75.76 μM)
CYP3A4, NF-κB, p38 MAPK, and Akt. Curcumenol is a potent CYP3A4 inhibitor with an IC50 of 12.6 μM. It suppresses Akt-mediated NF-κB activation and p38 MAPK signaling pathway. The compound also targets NADPH-oxidase, p65, and IκB. |
|---|---|
| ln Vitro |
Nitric oxide (NO) production, pro-inflammatory cytokines (IL-6) and (TNF-α) and pro-inflammatory protein expression, iNOS, and COX-2 expression are all significantly reduced by curcumenol in response to LPS. Hepatoprotective qualities of curcumenol have also been demonstrated. By preventing the phosphorylation of Akt, curcumenol can reduce the NF-B activity that LPS causes. Its administration significantly reduces the phosphorylation of p38 MAPK caused by LPS, but not JNK or ERK[1]. With an IC50 value of 12.6 1.3 M, curcumenol significantly reduces the activity of CYP3A4. With a Ki of 10.8 μM, kinetic analysis demonstrates curcumenol's competitive inhibition of testosterone 6β-hydroxylation activity (CYP3A4)[2].
Curcumenol suppresses Akt-mediated NF-κB activation and p38 MAPK signaling pathway in LPS-stimulated BV-2 microglial cells. It is a potent CYP3A4 inhibitor with an IC50 of 12.6 μM. Curcumenol possesses neuroprotective, anti-inflammatory, anti-tumor, and hepatoprotective activities. |
| ln Vivo |
In a sterile 96-well plate with a flat bottom, BV-2 cells are seeded. The following day, the cells are allowed to adhere. The cells are first pretreated with different concentrations of curcumenol for 2 hours, then exposed to LPS (0.4 μg/mL) for 12 to 24 hours.
In vivo, curcumenol has been studied for its neuroprotective, anti-inflammatory, anti-tumor, and hepatoprotective activities. The compound's ability to suppress NF-κB activation and inhibit CYP3A4 suggests potential therapeutic applications in inflammation, cancer, and liver diseases. Further in vivo studies are needed to fully characterize its therapeutic potential. |
| Enzyme Assay |
In vitro enzyme assays for curcumenol involve measuring its inhibition of CYP3A4 activity. CYP3A4 is incubated with a fluorogenic substrate and various concentrations of curcumenol. The production of fluorescent product is measured, and IC50 values (12.6 μM) are determined from concentration-response curves. NF-κB and p38 MAPK activity can be measured using reporter gene assays or phosphorylation-specific antibodies.
|
| Cell Assay |
In vitro cellular assays for curcumenol involve treating cells (such as BV-2 microglial cells) with the compound and measuring inflammatory responses, NF-κB activation, and MAPK signaling. Cells are treated with various concentrations of curcumenol and stimulated with LPS. Cytokine production is measured by ELISA. NF-κB activation and MAPK phosphorylation are assessed by Western blot.
|
| Animal Protocol |
In vivo animal studies for curcumenol typically involve administration to rodent models of inflammation, cancer, or liver disease. Efficacy is assessed by measuring inflammatory markers, tumor growth, or liver function. Curcumenol has neuroprotective, anti-inflammatory, anti-tumor, and hepatoprotective activities. Further studies are needed to fully characterize its in vivo efficacy.
|
| ADME/Pharmacokinetics |
Curcumenol has a molecular weight of 234.33 and a molecular formula of C15H22O2. It is soluble in DMF (10 mg/mL), DMSO (5 mg/mL), ethanol (3 mg/mL), and PBS (pH 7.2, 0.3 mg/mL). The compound is a potent CYP3A4 inhibitor. Further pharmacokinetic studies are needed.
|
| Toxicity/Toxicokinetics |
Preclinical toxicity studies of curcumenol are limited. The compound possesses neuroprotective, anti-inflammatory, anti-tumor, and hepatoprotective activities. Comprehensive toxicological evaluation is needed before clinical development. The compound should be handled with appropriate safety precautions.
|
| References | |
| Additional Infomation |
According to reports, curcumin is found in turmeric, artemisia, and other organisms for which relevant data exists.
Curcumenol is a bioactive compound derived from Curcuma zedoaria with neuroprotective, anti-inflammatory, anti-tumor, and hepatoprotective activities. It is a potent CYP3A4 inhibitor with an IC50 of 12.6 μM. Curcumenol suppresses Akt-mediated NF-κB activation and p38 MAPK signaling pathway in LPS-stimulated BV-2 microglial cells. It is a valuable natural compound for research in inflammation and cancer. |
| Molecular Formula |
C15H22O2
|
|---|---|
| Molecular Weight |
234.339
|
| Exact Mass |
234.161
|
| Elemental Analysis |
C, 76.88; H, 9.46; O, 13.65
|
| CAS # |
19431-84-6
|
| Related CAS # |
19431-84-6
|
| PubChem CID |
167812
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
349.3±42.0 °C at 760 mmHg
|
| Flash Point |
146.7±22.1 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.553
|
| LogP |
3.4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
17
|
| Complexity |
430
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
O1[C@@]2(C([H])=C(C([H])([H])[H])[C@]3([H])C([H])([H])C([H])([H])[C@]([H])(C([H])([H])[H])[C@]13C([H])([H])/C/2=C(/C([H])([H])[H])\C([H])([H])[H])O[H]
|
| InChi Key |
ISFMXVMWEWLJGJ-NZBPQXDJSA-N
|
| InChi Code |
InChI=1S/C15H22O2/c1-9(2)13-8-14-11(4)5-6-12(14)10(3)7-15(13,16)17-14/h7,11-12,16H,5-6,8H2,1-4H3/t11-,12-,14-,15+/m0/s1
|
| Chemical Name |
(1S,2S,5S,8R)-2,6-dimethyl-9-propan-2-ylidene-11-oxatricyclo[6.2.1.01,5]undec-6-en-8-ol
|
| Synonyms |
Curcumenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 46~125 mg/mL (196.3~533.4 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (8.88 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (8.88 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (8.88 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2673 mL | 21.3365 mL | 42.6730 mL | |
| 5 mM | 0.8535 mL | 4.2673 mL | 8.5346 mL | |
| 10 mM | 0.4267 mL | 2.1337 mL | 4.2673 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
